Publications

2015

• Avis en réponse à la saisine HCB - dossier NL-2005-23. Paris, le 21 octobre 2015
  
  • Comité Scientifique Du Haut Conseil Des Biotechnologies .
  • Bagnis Claude
  • Bar-Hen Avner
  • Barny Marie Anne M. A.
  • Bellivier Florence
  • Berny Philippe
  • Bertheau Yves
  • Boireau Pascal
  • Brévault Thierry
  • Chauvel Bruno B.
  • Coléno François
  • Couvet Denis
  • Dassa Elie
  • de Verneuil Hubert
  • Eychenne Nathalie
  • Franche Claudine
  • Guerche Philippe
  • Guillemain Joël
  • Hernandez Raquet Guillermina
  • Jestin André
  • Klonjkowski Bernard
  • Lavielle Marc
  • Le Corre Valérie V.
  • Lemaire Olivier O.
  • Lereclus Didier
  • Maximilien Rémi
  • Meurs Eliane
  • Moreau de Bellaing Cédric
  • Naffakh Nadia
  • Négre Didier
  • Noyer Jean-Louis
  • Ochatt Sergio
  • Pages Jean-Christophe
  • Parzy Daniel
  • Regnault-Roger Catherine
  • Renard Michel
  • Saindrenan Patrick
  • Simonet Pascal
  • Troadec Marie-Bérengère
  • Vaissière Bernard
  • Vilotte Jean-Luc
  , 2015, pp.39 p.. Le Haut Conseil des biotechnologies (HCB) a été saisi le 17 juillet 2015 par les autorités compétentes françaises (le ministère de l’Agriculture, de l’Agroalimentaire et de la Forêt) d’une demande d’avis relative au dossier EFSA-GMO-NL-2005-23 de demande d’autorisation de mise sur le marché du maïs génétiquement modifié 59122 pour la culture, l’importation, la transformation, l’alimentation humaine et animale. Ce dossier a été déposé conjointement par les sociétés Pioneer Hi-Bred International et Mycogen Seeds c/o Dow AgroSciences LLC sur le fondement du règlement (CE) n°1829/2003 auprès de l’Autorité européenne de sécurité des aliments via les autorités compétentes néerlandaises, sous la référence EFSA-GMO-NL-2005-23. Par cette saisine, les autorités compétentes françaises consultent le HCB au stade ultime de la préparation au vote des Etats membres à la Commission européenne. Le Comité scientifique (CS)2 du HCB a examiné le dossier en séance du 24 septembre 2015 sous la présidence de Jean-Christophe Pagès. Le présent avis a été adopté par voie électronique le 21 octobre 2015 et publié le 2 décembre 2015.
• Monotone numerical schemes and feedback construction for hybrid control systems
  
  • Ferretti Roberto
  • Zidani Hasnaa
  Journal of Optimization Theory and Applications, Springer Verlag, 2015, 165 (2), pp.507-531. Hybrid systems are a general framework which can model a large class of control systems arising whenever a collection of continuous and discrete dynamics are put together in a single model. In this paper, we study the convergence of monotone numerical approximations of value functions associated to control problems governed by hybrid systems. We discuss also the feedback reconstruction and derive a convergence result for the approximate feedback control law. Some numerical examples are given to show the robustness of the monotone approximation schemes. (10.1007/s10957-014-0637-0)
  DOI : 10.1007/s10957-014-0637-0
• Fine properties of the subdifferential for a class of one-homogeneous functionals
  
  • Chambolle Antonin
  • Goldman Michael
  • Novaga Matteo
  Advances in Calculus of Variation, Walter de Gruyter GmbH, 2015. We collect here some known results on the subdifferential of one-homogeneous functionals, which are anisotropic and nonhomogeneous variants of the total variation and establish a new relationship between Lebesgue points of the calibrating field and regular points of the level lines of the corresponding calibrated function.
• Prediction of Response to Temozolomide in Low-Grade Glioma Patients Based on Tumor Size Dynamics and Genetic Characteristics
  
  • Mazzocco P
  • Barthélémy Célia
  • Kaloshi G
  • Lavielle Marc
  • Ricard D
  • Idbaih A
  • Psimaras D
  • Renard M-A
  • Alentorn A
  • Honnorat J
  • Delattre J-y
  • Ducray F
  • Ribba B
  CPT: Pharmacometrics and Systems Pharmacology, American Society for Clinical Pharmacology and Therapeutics ; International Society of Pharmacometrics, 2015, 4 (12), pp.728–737. Both molecular profiling of tumors and longitudinal tumor size data modeling are relevant strategies to predict cancer patients' response to treatment. Herein we propose a model of tumor growth inhibition integrating a tumor's genetic characteristics (p53 mutation and 1p/19q codeletion) that successfully describes the time course of tumor size in patients with low-grade gliomas treated with first-line temozolomide chemotherapy. The model captures potential tumor progression under chemotherapy by accounting for the emergence of tissue resistance to treatment following prolonged exposure to temozolomide. Using information on individual tumors' genetic characteristics, in addition to early tumor size measurements, the model was able to predict the duration and magnitude of response, especially in those patients in whom repeated assessment of tumor response was obtained during the first 3 months of treatment. Combining longitudinal tumor size quantitative modeling with a tumor''s genetic characterization appears as a promising strategy to personalize treatments in patients with low-grade gliomas. WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? þ First-line temozolomide is frequently used to treat low-grade gliomas (LGG), which are slow-growing brain tumors. The duration of response depends on genetic characteristics such as 1p/19q chromosomal codeletion, p53 mutation, and IDH mutations. However, up to now there are no means of predicting, at the individual level, the duration of the response to TMZ and its potential benefit for a given patient. • WHAT QUESTION DID THIS STUDY ADDRESS? þ The present study assessed whether combining longitudinal tumor size quantitative modeling with a tumor's genetic characterization could be an effective means of predicting the response to temozolomide at the individual level in LGG patients. • WHAT THIS STUDY ADDS TO OUR KNOWLEDGE þ For the first time, we developed a model of tumor growth inhibition integrating a tumor's genetic characteristics which successfully describes the time course of tumor size and captures potential tumor progression under chemotherapy in LGG patients treated with first-line temozolomide. The present study shows that using information on individual tumors' genetic characteristics, in addition to early tumor size measurements, it is possible to predict the duration and magnitude of response to temozolomide. • HOW THIS MIGHT CHANGE CLINICAL PHARMACOLOGY AND THERAPEUTICS þ Our model constitutes a rational tool to identify patients most likely to benefit from temozolomide and to optimize in these patients the duration of temozolomide therapy in order to ensure the longest duration of response to treatment. Response evaluation criteria such as RECIST—or RANO for brain tumors—are commonly used to assess response to anticancer treatments in clinical trials. 1,2 They assign a patient's response to one of four categories, ranging from " complete response " to " disease progression. " Yet, criticisms have been raised regarding the use of such categorical criteria in the drug development process, 3,4 and regulatory agencies have promoted the additional analysis of longitudinal tumor size measurements through the use of quantitative modeling. 5 Several mathematical models of tumor growth and response to treatment have been developed for this purpose. 6,7 These analyses have led to the (10.1002/psp4.54)
  DOI : 10.1002/psp4.54
• A conformal mapping algorithm for the Bernoulli free boundary value problem
  
  • Haddar Houssem
  • Kress Rainer
  Mathematical Methods in the Applied Sciences, Wiley, 2015. We propose a new numerical method for the solution of Bernoulli's free boundary value problem for harmonic functions in a doubly connected domain $D$ in $\real^2$ where an unknown free boundary $\Gamma_0$ is determined by prescribed Cauchy data on $\Gamma_0$ in addition to a Dirichlet condition on the known boundary $\Gamma_1$. Our main idea is to involve the conformal mapping method as proposed and analyzed by Akduman, Haddar and Kress~\cite{AkKr,HaKr05} for the solution of a related inverse boundary value problem. For this we interpret the free boundary $\Gamma_0$ as the unknown boundary in the inverse problem to construct $\Gamma_0$ from the Dirichlet condition on $\Gamma_0$ and Cauchy data on the known boundary $\Gamma_1$. Our method for the Bernoulli problem iterates on the missing normal derivative on $\Gamma_1$ by alternating between the application of the conformal mapping method for the inverse problem and solving a mixed Dirichlet--Neumann boundary value problem in $D$. We present the mathematical foundations of our algorithm and prove a convergence result. Some numerical examples will serve as proof of concept of our approach. (10.1002/mma.3708)
  DOI : 10.1002/mma.3708
• Nonlocal Curvature Flows
  
  • Chambolle Antonin
  • Morini Massimiliano
  • Ponsiglione Marcello
  Archive for Rational Mechanics and Analysis, Springer Verlag, 2015, 218 (3), pp.1263. This paper aims at building a unified framework to deal with a wide class of local and nonlocal translation-invariant geometric flows. We introduce a class of nonlocal generalized mean curvatures and prove the existence and uniqueness for the level set formulation of the corresponding geometric flows. We then introduce a class of generalized perimeters, whose first variation is an admissible generalized curvature. Within this class, we implement a minimizing movements scheme and we prove that it approximates the viscosity solution of the corresponding level set PDE. We also describe several examples and applications. Besides recovering and presenting in a unified way existence, uniqueness, and approximation results for several geometric motions already studied and scattered in the literature, the theory developed in this paper allows us to establish also new results. (10.1007/s00205-015-0880-z)
  DOI : 10.1007/s00205-015-0880-z
• Equivalence between Exact and Approximate Controllability for Finite-Dimensional Quantum Systems
  
  • Boscain Ugo
  • Gauthier Jean-Paul
  • Rossi Francesco
  • Sigalotti Mario
  , 2015.